<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533960</url>
  </required_header>
  <id_info>
    <org_study_id>RASUNOA-Prime</org_study_id>
    <nct_id>NCT02533960</nct_id>
  </id_info>
  <brief_title>Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime</brief_title>
  <acronym>RASUNOA-Prime</acronym>
  <official_title>Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an&#xD;
      investigator-initiated study, is a German multicenter, prospective, observational registry.&#xD;
      It is performed at about 50 certified stroke-units and supported by an unrestricted grant&#xD;
      from different pharmaceutical companies to the Heidelberg University Hospital. RASUNOA-Prime&#xD;
      is designed to assess the emergency management of acute ischemic and hemorrhagic stroke&#xD;
      patients with atrial fibrillation (AF) under different anticoagulation schemes pre stroke:&#xD;
      Non-vitamin K antagonist oral anticoagulants (NOAC), Vitamin K antagonists (VKA), and no&#xD;
      anticoagulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this observational cohort study is to assess routine emergency management&#xD;
      of acute stroke patients with AF under different anticoagulation schemes before the index&#xD;
      stroke.&#xD;
&#xD;
      The investigators will address the following aims and objectives:&#xD;
&#xD;
        1. Describing emergency management of stroke patients (IS and ICH) with AF in clinical&#xD;
           routine including early diagnostic, therapeutic and preventive procedures and assessing&#xD;
           variations in emergency management of patients with AF by anticoagulation schemes pre&#xD;
           stroke.&#xD;
&#xD;
        2. Identifying variations in risk of early complications (e.g. symptomatic secondary&#xD;
           intracerebral haemorrhage in ischemic stroke patients) with AF by different&#xD;
           anticoagulation schemes pre stroke.&#xD;
&#xD;
        3. Determining factors influencing outcome of stroke patients with AF at three months and&#xD;
           clarifying the potential influence of different anticoagulation schemes pre stroke.&#xD;
&#xD;
      The registry consists of 2 separate substudies that cover two different patient cohorts:&#xD;
      ischemic stroke and intracerebral hemorrhage.&#xD;
&#xD;
      The study will collect information from prospectively enrolling Neurology departments with&#xD;
      certified stroke units across Germany.&#xD;
&#xD;
      The principal investigator, Prof. Dr. med. Roland Veltkamp, is affiliated with Imperial&#xD;
      College London, UK, and Heidelberg University Hospital, Germany.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary hypothesis (ischemic stroke substudy)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of less than 2 weeks&quot;</time_frame>
    <description>Intracerebral hemorrhage complications (i.e. sICH, according to NINDS and SITS-MOST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary hypothesis (hemorrhagic stroke substudy)</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of relevant secondary hematoma expansion on follow-up neuroimaging (hematoma expansion of &gt;= 33% or 6 mL)</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">3832</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Oral Anticoagulation</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>NOAC</arm_group_label>
    <description>Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).&#xD;
Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VKA</arm_group_label>
    <description>Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).&#xD;
Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without OAC</arm_group_label>
    <description>Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.&#xD;
Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>not applicable (observational study)</intervention_name>
    <description>Observational study without study related intervention.</description>
    <arm_group_label>NOAC</arm_group_label>
    <arm_group_label>VKA</arm_group_label>
    <arm_group_label>Without OAC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute stroke patients with atrial fibrillation (AF) under different anticoagulation schemes&#xD;
        pre stroke [Non-vitamin K antagonists oral anticoagulants (NOAC, also referred to as novel&#xD;
        or new oral anticoagulants), Vitamin K antagonists (VKA), and no oral anticoagulation.&#xD;
        According to the type of stroke, patients will be enrolled in the ischemic or hemorrhagic&#xD;
        stroke substudy.&#xD;
&#xD;
        NOTE: As of July 2019, enrollment in the ischemic stroke substudy was terminated due to&#xD;
        achievement of the targeted enrolling numbers.&#xD;
&#xD;
        NOTE: As of April 2021, enrollment in the intracerebral hemorrhage substudy was terminated&#xD;
        due to achievement of the targeted enrolling numbers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Ischemic stroke substudy:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Acute ischemic stroke with either symptoms lasting â‰¥ 24h or evidence of infarction in&#xD;
             brain imaging&#xD;
&#xD;
               -  Anticoagulation with NOAC&#xD;
&#xD;
               -  Anticoagulation with VKA&#xD;
&#xD;
               -  No anticoagulation&#xD;
&#xD;
          -  Previous/present atrial fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Symptom-onset &gt; 24 h&#xD;
&#xD;
        Hemorrhagic stroke substudy:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Acute primary intracerebral hemorrhage&#xD;
&#xD;
          -  - a) Anticoagulation with NOAC&#xD;
&#xD;
          -  - b) Anticoagulation with VKA&#xD;
&#xD;
          -  - c) No anticoagulation&#xD;
&#xD;
          -  Previous/present atrial fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Symptom-onset &gt; 24 h&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Veltkamp, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University Hospital, Department of Neurology, Heidelberg, Germany; Department of Stroke Medicine, Imperial College London, London, United Kingdom.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1177/2396987318812644</url>
    <description>Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime)</description>
  </link>
  <reference>
    <citation>Haas K, Purrucker JC, Rizos T, Heuschmann PU, Veltkamp R. Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J. 2019 Jun;4(2):181-188. doi: 10.1177/2396987318812644. Epub 2018 Dec 17.</citation>
    <PMID>31259266</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Prof. Roland Veltkamp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Registry of Acute Stroke Under Novel Oral Anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

